Comparative Pharmacology
Head-to-head clinical analysis: EPINEPHRINE versus LABETALOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPINEPHRINE versus LABETALOL HYDROCHLORIDE.
EPINEPHRINE vs LABETALOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that stimulates alpha-1, alpha-2, beta-1, beta-2, and beta-3 adrenergic receptors. Its effects include vasoconstriction (alpha-1), bronchodilation (beta-2), increased heart rate and contractility (beta-1), and relaxation of uterine and bladder smooth muscle.
Labetalol is a non-selective beta-adrenoceptor blocker and selective alpha-1 adrenoceptor blocker. It reduces myocardial contractility, heart rate, and peripheral vascular resistance.
0.3-0.5 mg IM (auto-injector or syringe) every 5-15 minutes as needed for anaphylaxis; IV: 0.1-0.5 mg (1-10 mcg/min infusion) for hemodynamic support.
Oral: Initial 100 mg twice daily, titrate up to 200-400 mg twice daily; maximum 2400 mg/day. IV: 20 mg slow IV over 2 minutes, then 40-80 mg every 10 minutes as needed up to 300 mg total; or continuous IV infusion at 0.5-2 mg/min.
None Documented
None Documented
Clinical Note
moderateEpinephrine + Torasemide
"Epinephrine may increase the hypokalemic activities of Torasemide."
Clinical Note
moderateNorepinephrine + Torasemide
"Norepinephrine may increase the hypokalemic activities of Torasemide."
Clinical Note
moderateNorepinephrine + Etacrynic acid
"Norepinephrine may increase the hypokalemic activities of Etacrynic acid."
Clinical Note
moderateEpinephrine + Etacrynic acid
"Epinephrine may increase the hypokalemic activities of Etacrynic acid."
1-2 minutes (intravenous); clinical effect termination primarily due to rapid uptake and metabolism, not elimination half-life.
Terminal elimination half-life: 6-8 hours. In renal impairment, half-life may be slightly prolonged but not clinically significant; in hepatic impairment, half-life may be significantly prolonged.
Primarily hepatic metabolism via catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO); renal excretion of metabolites (inactive) and small fraction (<5%) unchanged.
Primarily hepatic metabolism; ~5% excreted unchanged in urine; ~55-60% as glucuronide conjugates in urine; fecal excretion <5%.
Category A/B
Category A/B
Alpha/Beta Agonist
Alpha/Beta-Blocker